文献速递肝病消化道肿瘤与早癌

重新审视肝细胞癌患者的管理:与肝移植相关的风险评分(HALTHCC)纵向评估可改善消融等待策略

Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
PubMed 文献 · Hepatology · 2018-01-01

这项多中心回顾性研究纳入2002至2014年间419例因肝细胞癌等待肝移植的患者,其中351例接受局部区域治疗、68例未接受。纵向计算HALTHCC等评分,发现HALTHCC越接近剔除时预测意向治疗结局越好,局部区域治疗后HALTHCC变化比mRECIST更敏感,且与意向治疗死亡独立相关。

要点

  • HALTHCC越接近剔除时预测意向治疗结局越好,剔除前即刻C指数为0.742(0.643-0.790)。
  • 局部区域治疗后HALTHCC变化比mRECIST对风险变化更敏感。
  • HALTHCC评分及局部区域治疗前后百分比变化与意向治疗死亡独立相关。

核心结论

  • HALTHCC在评估等待肝移植患者的肿瘤风险方面更优,且其效用随时间增加。
  • 局部区域治疗后HALTHCC相对变化在分层剔除、死亡和移植后复发风险方面优于mRECIST。
  • 随着对移植后结局估计的改善,考虑使用HALTHCC而非仅等待时间进行分配是合理的。
  • 本研究支持视角从列表转向分配,以更好地利用宝贵的供体器官。

研究设计与样本

  • 多中心回顾性研究,2002年至2014年纳入419例因肝细胞癌列入肝移植等待名单的患者。
  • 等待期间接受局部区域治疗队列351例,无局部区域治疗对照组68例。
  • 纵向整合2085次影像学检查与实验室数据计算HALTHCC、MORAL、Metroticket 2.0和甲胎蛋白评分。
  • 采用Cox比例风险模型评估HALTHCC及局部区域治疗前后变化与意向治疗生存的关联,并以Harrell C指数评估效用。

主要发现

  • HALTHCC越接近剔除时预测意向治疗结局越好(P < 0.0001),剔除前即刻C指数为0.742(0.643-0.790)。
  • 意向治疗结局包括肝移植309例和剔除110例。
  • 局部区域治疗后HALTHCC变化(Delta-HALTHCC)比mRECIST对风险变化更敏感。
  • HALTHCC评分与意向治疗死亡独立相关,每增加1分风险比=1.105(1.045-1.169)。
  • 局部区域治疗前后HALTHCC百分比变化与意向治疗死亡独立相关,每变化1%风险比=1.014(1.004-1.024)。

临床怎么用

  • 作者认为,随着对移植后结局估计的改善,考虑使用HALTHCC而非仅等待时间进行分配是合理的。
  • 作者认为本研究支持视角从列表转向分配,以更好地利用宝贵的供体器官。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Patients with hepatocellular carcinoma (HCC) are screened at presentation for appropriateness of liver transplantation (LT) using morphometric criteria, which poorly specifies risk. Morphology is the crux of measuring tumor response to locoregional therapy (LRT) using modified Response Evaluation Criteria in Solid Tumors (mRECIST). This study investigated the utility of following a continuous risk score (hazard associated with liver transplantation in hepatocellular carcinoma; HALTHCC) to longitudinally assess risk. This multicenter, retrospective study from 2002 to 2014 enrolled 419 patients listed for LT for HCC. One cohort had LRT while waiting (n = 351), compared to the control group (n = 68) without LRT. Imaging studies (n = 2,085) were collated to laboratory data to calculate HALTHCC, MORAL, Metroticket 2.0, and alpha fetoprotein (AFP) score longitudinally. Cox proportional hazards evaluated associations of HALTHCC and peri-LRT changes with intention-to-treat (ITT) survival (considering dropout or post-LT mortality), and utility was assessed with Harrell's C-index. HALTHCC better predicted ITT outcome (LT = 309; dropout = 110) when assessed closer to delisting (P < 0.0001), maximally just before delisting (C-index, 0.742 [0.643-0.790]). Delta-HALTHCC post-LRT was more sensitive to changes in risk than mRECIST. HALTHCC score and peri-LRT percentage change were independently associated with ITT mortality (hazard ratio = 1.105 [1.045-1.169] per point and 1.014 [1.004-1.024] per percent, respectively). CONCLUSIONS: HALTHCC is superior in assessing tumor risk in candidates awaiting LT, and its utility increases over time. Peri-LRT relative change in HALTHCC outperforms mRECIST in stratifying risk of dropout, mortality, and recurrence post-LT. With improving estimates of post-LT outcomes, it is reasonable to consider allocation using HALTHCC and not just waiting time. Furthermore, this study supports a shift in perspective, from listing to allocation, to better utilize precious donor organs. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Firl DJ, Kimura S, McVey J, et al. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology. 2018. PMID: 29604231. doi:10.1002/hep.29907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。